Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Review of the Historical Literature and Its Role in the Era of Targeted Molecular Therapy. (23rd January 2014)

• Record Type: Journal Article
• Authors: Aslam, Muhammad Z.; Matthews, P. N.
• Other Names: Autorino R. Academic Editor.; Ku J. H. Academic Editor.
• Is Part Of: ISRN urology. Volume 2014(2014)
• Publication Date: 2014-01-23
• Subjects: Urology -- Periodicals; Urologic Diseases; Urology; Periodical; Periodicals; Fulltext; Internet Resources; Periodicals; Electronic journals; 616.6
• DOI: 10.1155/2014/717295
• Languages: English
• ISSNs: 2090-5807

Abstract

Abstract : Renal cell carcinoma presents with metastatic disease in approximately 30% cases. While surgical intervention remains the standard of care for organ confined disease, its role is limited in the management of metastatic disease. Over the last decade, cytoreductive nephrectomy prior to immunotherapy has demonstrated significant improvement in overall survival for appropriately selected patients. This review summarizes the evidence for the role of cytoreductive nephrectomy in combination with immunotherapy and discusses its potential role in the current era of targeted molecular therapy.